Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Arno Therapeutics, Inc. (ARNI)
Flemington, NJ, US
Arno Therapeutics, Inc., headquartered in Flemington, New Jersey, operates as a biopharmaceutical enterprise focused on discovering and advancing treatments for cancer and other severe health conditions. The company's developmental portfolio includes several key compounds: Onapristone, a type 1 anti-progestin hormone blocker, is currently undergoing Phase I/II clinical trials. This therapeutic is being investigated for its efficacy in treating various solid tumors, such as breast and endometrial cancers in post-menopausal women, and advanced castration-resistant prostate cancer in men. AR-12, an orally administered cancer therapy, has successfully completed Phase I clinical studies for solid tumors and hematological malignancies. Additionally, it is in pre-clinical development for potential applications against a range of microbial targets. AR-42, another innovative oral cancer treatment, is involved in a Phase I investigator-initiated clinical study, targeting both hematological malignancies and solid tumors. To support its research and development efforts, Arno Therapeutics has established licensing agreements with Invivis Pharmaceuticals, Inc., the Regents of the University of Minnesota, and the Ohio State University Innovation Foundation. The company also holds a co-development partnership with Leica Biosystems Newcastle Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +100.00% | +0.00% | +100.00% | -33.33% | -96.00% | -99.94% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-283.9% Q3'16: -158.6% (vs Q3'15)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q3'16: +196.5% (vs Q3'15)
-
Share dilution Biotechnology: -3.4%-17.7% ★ Q3'16: +119.1% (vs Q3'15)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.16× Q3'16: 0.00× (vs Q3'15)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-08-15 | Kariv Tomer | Director | P-Purchase | A | Common Stock | 349,168 | 0.35 | 122.2K | 1,696,495 | — | ↗ |
| 2016-08-15 | Belldegrun Arie | Director | P-Purchase | A | Common Stock | 714,285 | 0.35 | 250.0K | 2,262,838 | — | ↗ |
| 2016-04-07 | Zukiwski Alexander A | Director / Officer | A-Award | A | Stock Option (right to buy) | 1,196,070 | 0.37 | 442.5K | 1,196,070 | — | ↗ |
| 2016-04-07 | Kariv Tomer | Director | A-Award | A | Stock Option (right to buy) | 88,628 | 0.37 | 32.8K | 88,628 | — | ↗ |
| 2016-04-07 | Belldegrun Arie | Director | A-Award | A | Stock Option (right to buy) | 177,256 | 0.37 | 65.6K | 177,256 | — | ↗ |
| 2016-01-12 | Zukiwski Alexander A | Director / Officer | P-Purchase | A | Common Stock | 144,806 | 0.35 | 50.7K | 261,832 | — | ↗ |
| 2016-01-12 | Moorin Jay | Director | — | D | Common Stock | 0 | 0.00 | — | 642,858 | — | ↗ |
| 2016-01-12 | Kariv Tomer | Director | P-Purchase | A | Common Stock | 206,986 | 0.35 | 72.4K | 393,968 | — | ↗ |
| 2016-01-12 | Belldegrun Arie | Director | P-Purchase | A | Common Stock | 714,285 | 0.35 | 250.0K | 858,094 | — | ↗ |
| 2014-12-31 | Zukiwski Alexander A | Officer | — | D | Common Stock | 0 | 0.00 | — | 117,026 | — | ↗ |
| 2014-12-31 | Kariv Tomer | Director | — | I | Common stock | 0 | 0.00 | — | 186,982 | — | ↗ |
| 2014-12-31 | Belldegrun Arie | Director | — | I | Common Stock | 0 | 0.00 | — | 174,644 | — | ↗ |
| 2014-10-28 | Zukiwski Alexander A | Officer | D-Return | D | 2013 Series E Warrants (right to buy) | 41,666 | 2.40 | 100.0K | 0 | — | ↗ |
| 2014-10-28 | Kariv Tomer | Director | D-Return | D | 2013 Series E Warrants (right to buy) | 59,558 | 2.40 | 142.9K | 0 | — | ↗ |
| 2014-10-28 | Belldegrun Arie | Director | A-Award | A | 2012 Series B Warrants (right to buy) | 62,500 | 2.40 | 150.0K | 62,500 | — | ↗ |
| 2014-01-24 | Zukiwski Alexander A | Officer | A-Award | A | Stock Option (right to buy) | 711,301 | 2.90 | 2.06M | 711,301 | — | ↗ |
| 2014-01-24 | THURMAN RANDY H | Director | A-Award | A | Stock Option (right to buy) | 34,224 | 2.90 | 99.2K | 34,224 | — | ↗ |
| 2014-01-24 | Kariv Tomer | Director | A-Award | A | Stock Option (right to buy) | 34,224 | 2.90 | 99.2K | 34,224 | — | ↗ |
| 2014-01-24 | Belldegrun Arie | Director | A-Award | A | Stock Option (right to buy) | 68,448 | 2.90 | 198.5K | 68,448 | — | ↗ |
| 2013-11-04 | Zukiwski Alexander A | Officer | A-Award | A | Stock Option (right to buy) | 316,389 | 2.40 | 759.3K | 316,389 | — | ↗ |
| 2013-11-04 | THURMAN RANDY H | Director | A-Award | A | Stock Option (right to buy) | 68,448 | 2.40 | 164.3K | 68,448 | — | ↗ |
| 2013-11-04 | Kariv Tomer | Director | A-Award | A | Stock Option (right to buy) | 68,448 | 2.40 | 164.3K | 68,448 | — | ↗ |
| 2013-11-04 | Belldegrun Arie | Director | A-Award | A | Stock Option (right to buy) | 3,559,296 | 2.40 | 8.54M | 3,559,296 | — | ↗ |
| 2013-10-29 | Zukiwski Alexander A | Officer | P-Purchase | A | Common Stock | 41,666 | 2.40 | 100.0K | 117,026 | — | ↗ |
| 2013-10-29 | Kariv Tomer | Director | P-Purchase | A | Common Stock | 59,558 | 2.40 | 142.9K | 186,982 | — | ↗ |
| 2013-10-29 | Belldegrun Arie | Director | C-Conversion | A | Common Stock | 133,305 | 2.40 | 319.9K | 140,721 | — | ↗ |
| 2013-10-04 | WEXFORD CAPITAL LP | 10% Owner | S-Sale | D | Common Stock | 325 | 0.48 | 156.00 | 2,827,844 | — | ↗ |
| 2013-05-28 | Zukiwski Alexander A | Officer | J-Other | A | Common Stock | 9,667 | 0.30 | 2.9K | 29,667 | — | ↗ |
| 2013-05-28 | Kariv Tomer | Director | J-Other | A | Common Stock | 24,548 | 0.30 | 7.4K | 1,218,883 | — | ↗ |
| 2013-05-28 | Belldegrun Arie | Director | J-Other | A | Common Stock | 19,333 | 0.30 | 5.8K | 59,333 | — | ↗ |
| 2013-05-22 | THURMAN RANDY H | Director | P-Purchase | A | Common Stock | 2,500 | 0.50 | 1.3K | 10,000 | — | ↗ |
| 2013-05-21 | THURMAN RANDY H | Director | P-Purchase | A | Common Stock | 7,500 | 0.50 | 3.8K | 7,500 | — | ↗ |
| 2013-04-29 | Zukiwski Alexander A | Officer | J-Other | A | Common Stock | 10,000 | 0.30 | 3.0K | 20,000 | — | ↗ |
| 2013-04-29 | Kariv Tomer | Director | J-Other | A | Common Stock | 55,714 | 0.30 | 16.7K | 1,585,551 | — | ↗ |
| 2013-04-29 | Belldegrun Arie | Director | J-Other | A | Common Stock | 23,333 | 0.30 | 7.0K | 174,285 | — | ↗ |
| 2013-03-27 | Zukiwski Alexander A | Officer | J-Other | A | Common Stock | 10,000 | 0.30 | 3.0K | 10,000 | — | ↗ |
| 2013-03-27 | Kariv Tomer | Director | J-Other | A | Common Stock | 32,589 | 0.30 | 9.8K | 1,529,837 | — | ↗ |
| 2013-03-27 | Belldegrun Arie | Director | J-Other | A | Common Stock | 10,000 | 0.30 | 3.0K | 137,619 | — | ↗ |
| 2013-01-30 | THURMAN RANDY H | Director | A-Award | A | Stock Option (right to buy) | 200,000 | 0.30 | 60.0K | 200,000 | — | ↗ |
| 2013-01-25 | Zukiwski Alexander A | Officer | — | D | Stock Option (right to buy) | 97,500 | 0.30 | 29.3K | 0 | — | ↗ |
| 2013-01-25 | WEXFORD CAPITAL LP | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 418,876 | — | ↗ |
| 2013-01-25 | Kariv Tomer | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 54,725 | — | ↗ |
| 2013-01-25 | Belldegrun Arie | Director | — | D | Stock Option (right to buy) | 10,000 | 1.00 | 10.0K | 0 | — | ↗ |
| 2012-12-18 | Kariv Tomer | Director | — | I | Series A Warrants (right to buy) | 476,467 | 0.50 | 238.2K | 0 | — | ↗ |
| 2012-11-26 | Zukiwski Alexander A | Officer | — | D | Series A Warrants (right to buy) | 500,000 | 0.50 | 250.0K | 0 | — | ↗ |
| 2012-11-26 | Belldegrun Arie | Director | — | I | 8% Senior Convertible Debentures | 666,667 | 0.30 | 200.0K | 0 | — | ↗ |
| 2010-09-09 | WEXFORD CAPITAL LP | 10% Owner | — | I | Class A Warrants (right to buy) | 85,759 | 0.53 | 45.2K | 0 | — | ↗ |
| 2010-09-09 | Kariv Tomer | Director | — | I | Class A Warrants (right to buy) | 34,306 | 0.53 | 18.1K | 0 | — | ↗ |
| 2010-09-09 | Belldegrun Arie | Director | — | I | Class A Warrants (right to buy) | 10,000 | 0.53 | 5.3K | 0 | — | ↗ |
| 2008-09-08 | LENZ BRIAN | Officer | P-Purchase | A | Common Stock | 4,000 | 3.00 | 12.0K | 4,000 | — | ↗ |
| 2008-08-14 | LENZ BRIAN | Officer | — | D | Stock Option (right to buy) | 440,000 | 2.75 | 1.21M | 0 | — | ↗ |
| 2008-06-02 | WEXFORD CAPITAL LP | 10% Owner | — | I | Warrants (right to buy) | 24,732 | 2.42 | 59.9K | 0 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David Tanen | Sec. | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ARNI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
